



APOLLON
F O R M U L A R I E S



DISCLAIMER

This presentation and any additional documented handed out at any meeting (together the “**Presentation Materials**”) are being supplied to you for information purposes only by Apollon Formularies Ltd (“**Apollon**” or the “**Company**”) in connection with the proposed placing of new ordinary shares in the Company (the “**Placing**”). There is no guarantee that the Placing will occur and the Presentation Materials are being furnished strictly for information purposes only.

Information contained in the Presentation Materials has been obtained from various sources. It has been verified to the best of the Company’s ability, however it has not been independently verified and no representation is made, nor warranty given by or on behalf of the Company or Peterhouse Capital Limited (“**Peterhouse**”) or any of their respective parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person’s respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions..

All information presented or contained in the Presentation Materials is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company, Peterhouse or any of their respective parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person’s respective directors, officers, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update the Presentation Materials or to provide the recipient with access to any additional information that may arise in connection with it.

The Presentation Materials do not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and neither the issue of the information nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. The Presentation Materials do not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The Presentation Materials are intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure upon which an investment decision could be made. Any investment decision should be made solely on the basis of an approved admission document (together with any supplementary admission document, if relevant) in relation to the proposed Placing. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment.

These Presentation Materials will be only addressed to and directed at persons (a) in the UK, who (i) have professional experience in matters relating to investments and are “investment professionals” within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “**Order**”), or are persons falling within Article 49(2)(a) to (d) of the Order and (ii) who are “Qualified Investors” (as defined in Article 2 of the Prospectus Regulation ((EU) 2017/1129)); or (b) are otherwise persons to whom it may lawfully be communicated (all such persons together being referred to as “relevant persons”) (“**Relevant Persons**”).

These Presentation Materials will be only addressed to and directed at persons (a) in the UK, who (i) have professional experience in matters relating to investments and are “investment professionals” within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”) or are persons falling within Article 49(2)(a) to (d) of the Order and (ii) who are “Qualified Investors” (as defined in Article 2 of the Prospectus Regulation); or (b) are otherwise persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “**relevant persons**”).

This presentation should not be acted or relied upon by persons who are not relevant persons. Any investment or investment activity to which this communication relates is only available to relevant persons and will be engaged in only with relevant persons.

The ordinary shares mentioned in these Presentation Materials have not been and will not be, registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), or under any U.S. State securities laws, and may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. Neither the U.S. Securities and Exchange Commission nor any U.S. state regulatory authority has approved the ordinary shares to be offered or the terms of such offering or passed upon the accuracy or adequacy of the presentation and these Presentation Materials. Any representation to the contrary is a criminal offence.

These Presentation Materials are not for distribution outside the United Kingdom (save for in circumstances which fall within an exemption from registration or authorisation requirements) and in particular, they or any copy of them should not be distributed, directly or indirectly, by any means (including electronic transmission) either to persons with addresses in the European Economic Area, the United States of America, Canada, Australia, Japan, the Republic of South Africa, or to any of their citizens, nationals or residents, or to any corporation, partnership or other entity created or organized under the laws of such jurisdictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such other jurisdictions.

Past performance is not a guarantee for future returns. The distribution, reproduction or other use of all or any part of these Presentation Materials is prohibited. The Presentation Materials must not be reproduced in whole or in part, nor may they be used for any purpose other than that for which they have been submitted, without the prior written consent of the Company.

By accepting a copy of the Presentation Materials you agree to be bound by the foregoing provisions.

Forward-looking Statements

This presentation may contain forward-looking statements. These statements relate to the future prospects, developments and business strategies of the Company and its subsidiaries (the “**Group**”). Forward-looking statements are identified by the use of such terms as “believe”, “could”, “envisage”, “estimate”, “potential”, “intend”, “may”, “plan”, “will” or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in the presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors are advised to seek their own financial advice and do not rely on the accuracy or completeness of this material.

This presentation should be considered a draft that is constantly being updated. Should you have an interest in investing you should request the most recent version

Apollon's strategy is to become a global medical cannabis company licensed to develop full spectrum formulations based on real life clinical patient data

WHO IS APOLLON?

- A licensed full spectrum medical cannabis company operating in Jamaica
- Aim is commercialise a suite of full spectrum medical cannabis products and therapeutic applications
- Licensed and approved to cultivate, process, manufacture, perform research and develop, retail therapy as well as sell medical cannabis in Jamaica



**CULTIVATION,
PROCESSING &
EXTRACTION**

**RESEARCH &
DEVELOPMENT**

**MEDICALLY
SUPERVISED
TRIALS**

**BESPOKE
TREATMENTS
AND PRODUCTS**

RETAIL PRODUCT SALES



STRATEGY

Our strategy is to become the premiere global medical cannabis company legally licensed to develop successful personalised clinical treatments utilizing artificial intelligence on clinical trial patient data

Apollon's R&D License will allow drug discovery using THC and other cannabinoids. It is our intention to be one of the very few listed European companies able to undertake medically supervised trials inclusive of THC to develop new Apollon therapeutics and formulations

- 1.** Intends to undertake medically supervised trials using full spectrum medical cannabis oils and formulations
- 2.** Intends to identify disease and patient specific formulations for patient treatment
- 3.** To identify additional full spectrum medical cannabis formulations that are based on supervised trials
- 4.** Will implement quality controlled legal cultivation of medical cannabis strains following listing
- 5.** Be capable of providing consistent dosing globally and legally
- 6.** Patented formulas to be made available for third party licensing
- 7.** Patented formulations, along with clinically proven data, allow for potential partnerships with 'Big Pharma'

BOARD



STEPHEN D. BARNHILL, MD, BCLD | Director

A physician trained in Laboratory Medicine and Board Certified by the American Board of Bioanalysis. His patents were part of the intellectual property portfolio that won 1st Place out of 1,600 and was awarded the MICO award from MDB Capital for the most disruptive intellectual property portfolio. Inventor on more than 40 patents (US and International). Former Chairman and CEO of both private and publicly traded Biotech companies.



NICHOLAS F BARNHILL (NICK) | Director

As the Director of Operations and Cultivation Knowledge of AFI, he is responsible for providing general business direction and management oversight of the company's medical cannabis industry initiatives including: the procurement of licenses, and the establishment of lawful, quality production capabilities. He is involved in the supervision and accomplishment of certain cultivation and operational objectives involving the growth and procurement of raw materials and the establishment of facilities for medical cannabis production in Jamaica. As the Director of Cultivation of AFJ Mr. N. Barnhill has been supervising all phases of the company's cultivation operations including: regulatory compliance to CLA standards and law regarding production, quality control, maintenance, receiving, storage and shipping.



KEVIN SHEIL | Director

A capital markets veteran with over 30 years' experience, Mr. Sheil has experience across a number of sectors. Kevin has worked as a consultant to an AI technology firm, providing valuable input as Apollon continues to grow its line of AI-determined patient specific cannabis medicines and commercialise its unique 3D Pharmaceutical Printer. Mr. Sheil was a telecom sector specialist with Barclays, Credit Suisse and then Citibank where he worked for over 10 years and was consistently in the top rankings in Extel & Institutional Investor surveys. Mr Sheil worked as Head of Multi-Product Sales at Citibank and was responsible for broking all equity-based products as well as fixed Income into institutional accounts. Mr Sheil has also spent over nine years as a general equity fund manager for Trium Capital Managers



NICHOLAS INGRASSIA | Director


Nick is an oil & gas executive with over 19 years' experience across a wide range of corporate roles in-and-around the oil & gas industry including M&A, business development, financing, commercial, investor relations and operational functions. Nicholas started his career in banking with roles at Morgan Stanley (energy investment banking) and RBS (structured energy lending & debt advisory) before joining the oil & gas industry working for AIM-listed Valiant Petroleum plc, LSE-listed Salamander Energy plc and AIM-listed Faroe Petroleum Plc. Nicholas is currently Business Development Director and member of the executive team at AIM-listed Longboat Energy plc. He has MA Hons degree from the University of St Andrews in Ancient History.

ADVISORS



STEPHEN D. BARNHILL, MD, BCLD | Chairman

A physician trained in Laboratory Medicine and Board Certified by the American Board of Bioanalysis. His patents were part of the intellectual property portfolio that won 1st Place out of 1,600 and was awarded the MICO award from MDB Capital for the most disruptive intellectual property portfolio. Inventor on more than 40 patents (US and International). Former Chairman and CEO of both private and publicly traded Biotech companies.



ANTHONY HALL, MD, MDCM, FACS, FAANS | Head of Advisory Board

Specializes in Neurological Surgery and cannabis therapy. US Board Certified Brain and Spine Surgeon from McGill University. Dr Hall is an Associate Professor at Florida Int. University College of Medicine. Dr. Hall is also certified by the State of Florida to recommend medical cannabis to patients. Dr. Hall is also the Medical Director of Doc's Place International, Inc. Dr. Hall is Licensed to practice medicine in Canada, the US and Jamaica.



PAUL BURKE | Jamaican CEO

Mr. Burke a Former General Secretary of the Jamaican National Party from 2014-2016, Chairman and Founding Member of the National Alliance for the Legalization of Ganja, Project Manager and Founding Member of the Cannabis Commercial and Medicinal Task Force, Programme Director and Founding Member of the Ganja Growers and Producers Association of Jamaica and Chairman of the Jamaican Wellness and Health Network.



HERB FRITSCH, PH.D | Chief Science Officer

Clinical Chemist and was Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. During his 41 years at M.D. Anderson Cancer Center, Dr. Fritsche focused his research activities on the development and validation of cancer diagnostics. Dr. Fritsche has participated in the validation and FDA clearance process for every commercial serum tumor marker product currently in use in the United States.




MARGARET SPENCE, MB BS | Assistant Medical Director - Oncologist and Palliative Care Specialist

Fellow, Royal College of Radiologist, Diploma, Palliative Care. Consultant in Oncology and Palliative Medicine, Hope Institute



DANVILLE DAVIDSON | Director of Regulatory Affairs

Senior Advisor/Consultant to The Honourable Minister of Housing (Jamaica Labor Party- JLP), Water & Works, Group IT Manager, ICWI Group, Managing Director of the Spectrum Management Authority. Port Manager, Falmouth Cruise Ship Terminal. General Manager DPK (Jamaica) Limited. Advisor to the Prime Minister of Grenada



LICENCING

- ✓ Licensed for Medically Supervised Trials
- ✓ Licensed to cultivate cannabis
- ✓ Licensed Retail dispensary license
- ✓ Licensed for Retail Therapeutic Distribution
- ✓ Licensed Extraction Processing facility
- ✓ “Tier 3” Conditional Cultivation approval expected soon
- ✓ Licenses include R&D using THC

Apollon Formularies Ltd. indirectly holds 49% interest in Apollon Formularies Jamaica Limited (“AFJ”). AFJ is federally licensed in Jamaica

Export license expected Q2 2021

TARGETED REVENUE SOURCES

Patient's Treated at Jamaican International Treatment Facility

Potential for significant monthly revenue for both in patient treatments at the clinic as well as outpatient care

To Open Global Treatment Facility Franchises (Using Apollon Products and Protocols)

Strategy to create a globally recognized Apollon branded products inclusive of our 3D Printer technology.

Increase Apollon Product Sales in Jamaica and to identify partners in other regulated markets

To create Formulation I.P. & 3D printer Licensing & Royalties revenues streams

Expand the Legal Export of Apollon Oils and Products





LICENCED TO CONDUCT MEDICALLY SUPERVISED TRIALS ON PATIENTS

Apollon's Jamaica's Research and Development (Experimental) Licence allows the company to perform medically supervised trials overseen by the Jamaican Ministry of Health in addition to the medical team at Doc's Place Wellness Centre.

STRATEGY

Apollon's fully licenced full spectrum framework gives the company unrivalled ability to perform medically supervised trials. One of a handful of companies worldwide able to do this.

Jamaica's regulations mean that Apollon's medically supervised trials can be conducted using our own cannabis-based formulations along with placebo's to revealing the medicine's efficacy. Formulations are patentable.

APOLLON WILL MOVE QUICKLY TO EXPAND SALES AND DISTRIBUTION OF ITS EXISITING FORMULATIONS

PRODUCTS

It is the intention to offer the 7 formulations listed below for sale in its dispensary in Jamaica.

- Apollon NAUSEA
- Apollon PAIN
- Apollon SLEEP
- Apollon ANTI-INFLAMMATORY
- Apollon SEIZURES
- Apollon APPETITE
- Apollon CANCER (APM)



DOC'S PLACE INTERNATIONAL (under option)

Option to acquire Doc's Place International, Inc. was established to provide an in-patient medical cannabis treatment facility for use by patients needing access to prescribed medical cannabis

GLOBAL CENTRE OF EXCELLENCE FOR MEDICAL CANNABIS THERAPY - NEGRIL, JAMAICA



- ✓ Approved by the SRC and the Ministry of Science, Energy and Technology for the treatment of medical cannabis patients
- ✓ Currently eight treatment rooms with plans to expand to 130-person clinic via purchase of second clinic
- ✓ Company intends to secure additional dispensary locations as well seek international export markets
- ✓ Apollon will post IPO commence medically supervised trials on Humans

PROCESSING & OIL EXTRACTION


Apollon Holds a Oil Processing Licence For The Production of Cannabis Oils

- Apollon's owns and operates a processing laboratory at its facility in Negril, Jamaica
- Equipment is capable of producing high quality FULL spectrum medical cannabis oil (including THC)
- Target markets will include Jamaica as well as export to all countries where legal import is allowed
- Laboratory also manufactures Apollon's retail medical cannabis pharmaceuticals for sale via the company's dispensary
- Apollon will begin cultivation Q1 2021 of their APM medical cannabis plant strains



3D PRINTER

The Apollon 3D Pharmaceutical Printer provides a unique solution to transportation and regulation limitations for full spectrum cannabis products



APOLLON TRADEMARKED FORMULATION

ADVANTAGES


- Designed to overcome import/export regulations on cannabinoids and THC
- Apollon formulation medicines could be printed 'in house' using bio ink
 - Ensures consistency
 - Specific formulation 'recipes' can be emailed over to a printer
- Potential to revolutionizing cannabis drug manufacturing
- Requires the purchasing company to be fully licensed

POTENTIAL GLOBAL MARKETS

Apollon strategy is to franchise its wellness clinics as well as distribute its products globally

Apollon intends to target markets where medical cannabis is legal, in particular The UK, Canada, Greece & South Africa

As the cannabis industry grows and import regulations relax, Apollon will expand its THC containing products to a larger portion of the world



INVESTMENT HIGHLIGHTS

To become self funded via the sale of Apollon products through its dispensary and clinical trials


To optimise operations to create a low cost high quality production line of Apollon products

3D PHARMACEUTICAL PRINTER
Provide the ability to print standardised Apollon medicine anywhere in the world



CLINICAL TRIALS

To determine true efficacy for Apollon's cannabis-based medicines



To create additional medical cannabis products for sale backed by clinical trials

To create a globally recognised Apollon brand

GRANTED LICENCES
cultivation, processing, extraction, transportation, retail (therapeutic) and R&D

CONTACTS

Company

Dr. Stephen Barnhill:

stephen@apollon.org.uk

Chairman Apollon Formularise Ltd

Kevin Sheil:

kevin@apollon.org.uk

Director Apollon Formularies Ltd

Stene Jacobs:

stene@apollon.org.uk

Head of UK business development

Blytheweigh (Financial PR)

Megan Ray

megan.ray@blytheweigh.com

Alice McLaren

alice.mclaren@blytheweigh.com